| 1 |
31089832 | Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma. | 2019 May 14 |
4 |
| 2 |
29177954 | Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. | 2018 Jan |
4 |
| 3 |
27479651 | The expression of P-glycoprotein in leukemia cells is associated with the upregulated expression of nestin, a class 6 filament protein. | 2016 Sep |
2 |
| 4 |
26002042 | Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure. | 2015 Sep 18 |
1 |
| 5 |
24627218 | The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions. | 2014 Apr |
2 |
| 6 |
24659021 | No clinically significant drug interactions between lenalidomide and P‑glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers. | 2014 May |
3 |
| 7 |
21825263 | Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. | 2011 Sep 1 |
6 |